New scoring system aims to predict 30-Day survival for metastatic cancer patients

NCT ID NCT05100342

Recruiting now Knowledge-focused Sponsor: Indiana University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a simple scoring system to predict whether people with metastatic cancer will survive at least 30 days after starting palliative radiation therapy. The score uses lab results, emergency room visits, and cancer type. About 214 adults will join to see if the tool helps doctors make better treatment decisions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Locations

IU Health North / Schwarz Cancer Center
RECRUITING

Carmel, Indiana, 46032, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
IU Health West
RECRUITING

Avon, Indiana, 46123, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Methodist Hospital
RECRUITING

Indianapolis, Indiana, 46202, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.